Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasniqi, Eriseld, Pizzuti, Laura, Valerio, Maria Rosaria, Capomolla, Elisabetta, Botti, Claudio, Sanguineti, Giuseppe, Marchetti, Paolo, Anselmi, Elisabetta, Tomao, Silverio, Giordano, Antonio, Ficorella, Corrado, Cannita, Katia, Livi, Lorenzo, Meattini, Icro, Mauri, Maria, Greco, Filippo, Veltri, Enzo Maria, Michelotti, Andrea, Moscetti, Luca, Giotta, Francesco, Lorusso, Vito, Paris, Ida, Tomao, Federica, Santini, Daniele, Tonini, Giuseppe, Villa, Alice, Gebbia, Vittorio, Gamucci, Teresa, Ciliberto, Gennaro, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Vici, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040412/
https://www.ncbi.nlm.nih.gov/pubmed/33859534
http://dx.doi.org/10.7150/ijms.54996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040412/
https://www.ncbi.nlm.nih.gov/pubmed/33859534
http://dx.doi.org/10.7150/ijms.54996

Ejemplares similares